



Please type a plus sign inside this box → +

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

#4  
D/Dee  
9/23/02

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/884,384
		Filing Date	June 19, 2001
		First Named Inventor	Huda Y. Zoghbi
		Group Art Unit	1632
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission		Attorney Docket Number	HO-P01492US2

RECEIVED

SEP 19 2002

TECH CENTER

1600/2900

### ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Applicants believe no fees are due. However, if fees are due, please charge them  
to the account 06-2375 of Fulbright & Jaworski L.L.P. under Order No. P01492US2,  
from which the undersigned is authorized to withdraw.

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	FULBRIGHT & JAWORSKI L.L.P. Melissa L. Sistrunk, Reg. No. 45,579
Signature	
Date	Sept. 17, 2002

#### Transmittal

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No.  
EU186313425US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown  
below.

Dated: 9/17/02 Signature: Monica L. Thomas (Monica Thomas)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. **EU1867829254** in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated:

Signature:

(Monica Thomas)

SEP 19 2002

TECH CENTER 1600/2900

Docket No.: HO-P01492US2  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Huda Y. Zoghbi, et al.

Application No.: 09/884,384

Group Art Unit: 1632

Filed: June 19, 2001

Examiner: Not Yet Assigned

For: CHAPERONE SUPPRESSION OF ATAXIN-  
1 AGGREGATION AND ALTERED  
SUBCELLULAR PROTEASOME  
LOCALIZATION IMPLY PROTEIN  
MISFOLDING IN SCA1

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

Applicants submit two Form PTO-1449, the references of which are not supplied because they were previously cited by or submitted to the Office in prior U.S. Patent Application No. 09/321,916, filed May 28, 1999 and relied upon in this application for an earlier filing date under 35 U.S.C. 120. The original IDS was filed December 6, 1999, and a supplemental IDS was filed July 19, 2000. If re-submission of the references is required, please let the undersigned know for quick resolution.



While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P01492US2. A duplicate copy of this paper is enclosed.

Dated:

*Sept. 17, 2002*

Respectfully submitted,

By *Melissa L. Sistrunk*  
Melissa L. Sistrunk  
Registration No.: 45,579  
FULBRIGHT & JAWORSKI L.L.P.  
1301 McKinney, Suite 5100  
Houston, Texas 77010-3095  
(713) 651-3735  
(713) 651-5246 (Fax)  
Agent for Applicant



Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>				Docket No. (Optional) <b>P01492US1</b>		Application Number <b>09/321,916</b>				
				RECEIVED <b>SEP 19 2002</b>						
				Applicant: <b>Zoghbi, et al.</b>		Group Art Unit <b>1633</b>				
				Filing Date: <b>05/28/99</b>						
<b>U.S. PATENT DOCUMENTS</b> <b>TECH CENTER 1600/2900</b>										
EXAMINER INITIAL	DOCUMENT NUMBER			DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENT(S)</b>										
	DOCUMENT NUMBER			DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION	
									YES	NO
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>										
1.	Barkats, M. et al.; Adenovirus in the Brain: Recent Advances of Gene Therapy for Neurodegenerative Diseases; <i>Prog. In Neurobiol.</i> 55:333-341 (1998).									
2.	Barkats, M. et al.; Intrastriatal Grafts of Embryonic Mesencephalic Rat Neurons Genetically Modified Using an Adenovirus Encoding Human Cu/Zn Superoxide Dismutase; <i>Neuroscience</i> 78:703-713 (1997).									
3.	Beissinger, Martina and Buchner, Johannes; How Chaperones Fold Proteins; <i>Biol. Chem.</i> 379:245-259 (1998).									
4.	Bilang-Bleuel, A. et al.; Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease; <i>Proc. Natl. Acad. Sci. USA</i> 94: 8818-8823 (1997).									
5.	Blömer, U. et al.; Applications of gene therapy to the CNS; <i>Hum. Mol. Genet.</i> 5:1397-1404 (1996).									
6.	Bruening, W. et al.; Up-Regulation of Protein Chaperones Preserves Viability of Cells Expressing Toxic Cu/Zn Superoxide Dismutase Mutants Associated with Amyotrophic Lateral Sclerosis; <i>J. Neurochem.</i> 72:693-699 (1999).									
7.	Bukau, Bernd and Horwich, Arthur L.; The Hsp70 and Hsp60 Chaperone Machines; <i>Cell</i> 92:351-366 (1998).									
8.	Caughey, B. et al.; Congo Red Inhibition of Scrapie Agent Replication; <i>J. Virol.</i> 67:6270-6272 (1993).									
9.	Caughey, Byron and Race, Richard E.; Potent Inhibition of Scrapie-Associated PrP Accumulation by Congo Red; <i>J. Neurochem.</i> 59:768-771 (1992).									
10.	Caughey, Byron and Raymond, Gregory J.; Sulfated Polyanion Inhibition of Scrapie-Associated PrP Accumulation in Cultured Cells; <i>J. of Virol.</i> 67:643-650 (1993).									
11.	Cha, J-H. J.; et al.; Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease; <i>Phil. Trans. R. Soc. Lond.</i> 354:981-989 (1999).									
12.	Chai, Y. et al.; Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation <i>in vitro</i> ; <i>Hum. Mol. Gen.</i> 8:673-682 (1999).									
13.	Choi-Lundberg, D. L. et al.; Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy; <i>Science</i> 275:838-841 (1997).									
14.	Csermely, P. et al.; The 90-kDa Molecular Chaperone Family: Structure, Function, and Clinical Applications. A Comprehensive Review; <i>Pharmacol. Ther.</i> 79:129-168 (1998).									
15.	Cummings, C. J. et al.; Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1; <i>Nature Genet.</i> 19:148-154 (1998).									
16.	Cummings, Christopher J. and Huda Y. Zoghbi; Fourteen and counting: unraveling trinucleotide repeat diseases; <i>Hum. Mol. Gen.</i> 9:909-916 (2000).									
EXAMINER					DATE CONSIDERED					

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



RECEIVED

SEP 19 2002

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

TECH CENTER 1600/2900

Application Number  
09/321,916

Applicant:  
Zoghbi, et al.

Filing Date:  
05/28/99

Group Art Unit  
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENT(S)

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

17.	Cummings, C. J. et al.; Mutation of the E6-AP Ubiquitin Ligase Reduces Nuclear Inclusion Frequency While Accelerating Polyglutamine-Induced Pathology in <i>SCA1</i> Mice; <i>Neuron</i> X:879-892 (1999).
18.	Déglon, N.; Central Nervous System Delivery of Recombinant Ciliary Neurotrophic Factor by Polymer Encapsulated Differentiated C <sub>2</sub> C <sub>12</sub> Myoblasts; <i>Hum. Gene Ther.</i> 7:2135-2146 (1996).
19.	Doran S. E. et al.; Gene Expression from Recombinant Viral Vectors in the Central Nervous System after Blood-Brain Barrier Disruption; <i>Neurosurgery</i> 36:965-970 (1995).
20.	Emerich, D. F. et al.; Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease; <i>Nature</i> 386:395-399 (1997).
21.	Floyd, Jennifer A. and Hamilton, Bruce A.; Intranuclear Inclusions and the Ubiquitin-Proteasome Pathway: Digestion of a Red Herring?; <i>Neuron</i> 24(4):765-766 (1999).
22.	Giménez y Ribotta, M. et al.; Prevention of Motoneuron Death by Adenovirus-Mediated Neurotrophic Factors; <i>J. Neurosci. Res.</i> 48:281-285 (1997).
23.	Graham, Frank L. and Prevec, Ludvik; Chapter 11- Manipulation of Adenovirus Vectors; <i>Methods in Molecular Biology. Vol 7: Gene Transfer and Expression Protocols</i> ; E. J. Murray, Ed.; The Humana Press Inc.; p. 109-128 (1991).
24.	Haase, G. et al.; Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors; <i>Nature Medicine</i> 3:429-436 (1997).
25.	Hedera, P. et al.; Spastic paraparesis, ataxia, mental retardation (SPAR): a novel genetic disorder; (abstract).
26.	Hendrick, Joseph P. and Hartl, Franz-Ulrich; Molecular Chaperone Functions of Heat-Shock Proteins; <i>Annu. Rev. Biochem.</i> 62:349-384 (1993).
27.	Horellou, P. et al.; Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease; <i>NeuroReport</i> 6:49-53 (1994).
28.	Kaytor, Michael D. and Warren, Stephen T.; Aberrant Protein Deposition and Neurological Disease; <i>J. Biol. Chem.</i> 274:37507-37510 (1999).
29.	Kazemi-Esfarjani, Parsa and Benzer, Seymour; Genetic Suppression of Polyglutamine Toxicity in <i>Drosophila</i> ; <i>Science</i> 287:1837-1840 (2000).
30.	Kobayashi, Y. et al.; Chaperones Hsp70 and Hsp40 Suppress Aggregate Formation and Apoptosis in Cultured Neuronal Cells Expressing Truncated Androgen Receptor Protein with Expanded Polyglutamine Tract; <i>J. Biol. Chem.</i> 275:8772-8778 (2000).
31.	Kojima, H. et al.; Construction and Characterization of Adenoviral Vector Expressing Biologically Active Brain-Derived Neurotrophic Factor; <i>Biochem. Biophys. Res. Commun.</i> 212:712-717 (1995).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



SEP 17 2002

RECEIVED

SEP 19 2002

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket No. (Optional) **TO-1449** Application Number  
**P01492US1** **09/321,916**

Applicant:  
Zoghbi, et al.

Filing Date:  
05/28/99

Group Art Unit  
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENT(S)

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

32.	Koshy, Benna T. and Zoghbi Huda Y.; The CAG/Polyglutamine Tract Diseases: Gene Products and Molecular Pathogenesis; <i>Brain Pathol.</i> 7:927-942 (1997).					
33.	Krobitsch, Sylvia and Lindquist, Susan; Aggregation of huntington in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins; <i>Proc. Natl. Acad. Sci. USA</i> 97:1589-1594.					
34.	Le Gal La Salle, G. et al.; An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain; <i>Science</i> 259:988-990 (1993).					
35.	Lin, X et al.; Expanding Our Understanding of Polyglutamine Diseases through Mouse Models; <i>Neuron</i> 24:499-502 (1999).					
36.	Lowe, J. et al.; Ubiquitin is a Common Factor in Intermediate Filament Inclusion Bodies of Diverse Type in Man, Including those of Parkinson's Disease, Pick's Disease, and Alzheimer's Disease, as well as Rosenthal Fibres in Cerebellar Astrocytomas, Cytoplasmic Bodies in Muscle, and Mallory Bodies in Alcoholic Liver Disease; <i>J. of Pathol.</i> 155:9-15 (1988).					
37.	MacDonald, Marcy E.; <i>gadzoooks!</i> ; <i>Nature Genetics</i> 23:10-11 (1999).					
38.	Marber, M. S. et al.; Overexpression of the Rat Inducible 70-kD Heat Stress Protein in a Transgenic Mouse Increases the Resistance of the Heart to Ischemic Injury; <i>J. Clin. Invest.</i> 95:1446-1456 (1995).					
39.	Mayer, Matthias P. and Bukau, Bernd; Hsp70 Chaperone Systems: Diversity of Cellular Functions and Mechanism of Action; <i>Biol. Chem.</i> 379:261-268 (1998).					
40.	Mayer, R. J.; The ubiquitin/26S proteasome system and neurological disease - a personal view. (opinion).					
41.	Neuwelt; Edward A.; Cellular and Molecular Neurosurgery II - Comments; <i>Neurosurgery</i> 40:812-813 (1997).					
42.	Orr, Harry T. and Zoghbi, Huda Y.; Reversing Neurodegeneration: A Promise Unfolds; <i>Cell</i> 101:1-4 (2000).					
43.	Price, D. L. et al.; Neurodegenerative Diseases and Model Systems; <i>Neurodegenerative Diseases</i> ; LXI:725-738 (1996).					
44.	Priola, S. A. et al.; Porphyrin and Phthalocyanine Antiscrapie Compounds; <i>Science</i> 287:1503-1506.					
45.	Richardson, A. et al.; The ins and outs of a molecular chaperone machine; <i>TIBS</i> 23:138-143 (1998).					
46.	Sabaté, O. et al.; Adenovirus for Neurodegenerative Diseases: In Vivo Strategies and Ex Vivo Gene Therapy Using Human Neural Progenitors; <i>Clin. Neurosci.</i> 3:317-321 (1996).					
47.	Sato, T. et al.; Transgenic mice harboring a full-length human DRPLA gene with highly expanded CAG repeats exhibit severe disease phenotype (abstract).					

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



RECEIVED

SEP 19 2002

Sheet 4 of 4

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket No. (Optional)  
P01492US1

Application Number  
TECH CENTER 1600/2000 21,916

Applicant:  
Zoghbi, et al.

Filing Date:  
05/28/99

Group Art Unit  
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENT(S)

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

48.	Smith, David, F.; Sequence Motifs Shared between Chaperone Components Participating in the Assembly of Progesterone Receptor Complexes; <i>Biol. Chem.</i> 379:283-288 (1998).
49.	Supattapone; S. et al.; Elimination of priors by branched polyamines and implications for therapeutics; <i>Proc. Natl. Acad. Sci. USA</i> 96:14529-14534 (1999).
50.	Tagliavini, F. et al.; Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters; <i>Science</i> 276:1119-1122 (1997).
51.	Tran, Phuong B. and Miller, Richard J.; Aggregates in neurodegenerative disease: crowds and power?; <i>Trends Neurosci.</i> 22(5):194-197 (1999).
52.	Wagey, Ravenska T. E. and Krieger, Charles; Abnormalities of protein kinases in neurodegenerative diseases; <i>Prog. in Drug Res.</i> 51:135-183 (1998).
53.	Warrick, J. M. et al.; Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural Degeneration in <i>Drosophila</i> ; <i>Cell</i> ; 93:939-949 (1998).
54.	Wyttenbach, A. et al.; Effects of heat shock, heat shock protein 40 (Hdj-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease; <i>Proc. Natl. Acad. Sci. USA</i> 97:2898-2903 (2000).
55.	Xu, W. et al.; Regulation of Microphthalmia-Associated Transcription Factor MITF Protein Levels by Association with the Ubiquitin-Conjugating Enzyme hUBC9; <i>Exp. Cell. Res.</i> 255:135-143 (2000).
56.	Yamamoto, A. et al.; Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease; <i>Cell</i> ; 101:57-66 (2000).
57.	Yenari, M. A. et al.; Gene Therapy with HSP72 Is Neuroprotective in Rat Models of Stroke and Epilepsy; <i>Ann. Neurol.</i> 44:584-591 (1998).
58.	Zlokovic, Berislav V. and Apuzzo, Michael L. J.; Cellular and Molecular Neurosurgery: Pathways from Concept to Reality-Part I: Target Disorders and Concept Approaches to Gene Therapy of the Central Nervous System; <i>Neurosurgery</i> 40:789-803 (1997).
59.	Zoghbi, Huda Y. and Orr, Harry T.; Polyglutamine diseases: protein cleavage and aggregation; <i>Curr. Opin. In Neurobiol.</i> 9:566-570 (1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



RECEIVED

SEP 19 2002

Sheet 1 of 2

SEP 11 2002  
C12  
PATENT & TRADEMARK OFFICE

Sheet 2 of 2

		TANG, Y., et al, "A Role for HDJ-2/HSDJ in Correcting Subnuclear Trafficking, Transactivation, and Transrepression Defects of a Glucocorticoid Receptor Zinc Finger Mutant" MOLECULAR BIOLOGY OF THE CELL, Vol. 8, May 1997, pp 795-809
		LU, Z., et al, "The conserved Carboxyl Terminus and Zinc Finger-like Domain of the Co-chaperone Ydj1 Assist Hsp70 in Protein Folding" THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. 10, March 6, 1998, pp 5970-5978
		BUKAU, B., et al, "The Hsp70 and Hsp60 Chaperone Machines" CELL, Vol. 92, pp 351-366, February 6, 1998
		GLOVER, J.R., et al, "Hsp104, Hsp70, and Hsp40: A Novel Chaperone System that Rescues Previously Aggregated Proteins" CELL, Vol. 94, pp 73-82, July 10, 1998
		BUSH, K.T., et al, "Proteasome Inhibition Leads to a Heat-shock Response, Induction of Endoplasmic Reticulum Chaperones, and Thermotolerance" THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 272, No. 14, April 4, 1997, pp 9086-9092
		HENRY L. PAULSON, "Human Genetics '99: Trinucleotide Repeats Protein Fate in Neurodegenerative Proteinopathies: Polyglutamine Diseases John the (Mis)Fold" AM. J. HUM. GENET., 1999, 64:339-345
		ALVES-RODRIGUES, A., et al, "Ubiquitin, cellular inclusions and their roll in neurodegeneration" TRENDS NEUROSCI (1998) 21, 516-520
		BURRIGHT, E.N., et al, "SCA1 Transgenic Mice: A Model for Neurodegeneration Caused by an Expanded CAG Trinucleotide Repeat" CELL, Vol. 82, pp 937-948, September 22, 1995
		AARON CIECHANOVER, "The ubiquitin-proteasome pathway: on protein death and cell life" THE EMBO JOURNAL, Vol. 17, No. 24, pp 7151-7160, 1998
		PAULSON, H.L., et al, "Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3" NEURON, Vol. 19, pp 333-344, August, 1997
		SKINNER, P.J., et al, "Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures" LETTERS TO NATURE, #21, #1834 pp 971-974
		STENOIJEN, D.L., et al, "Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone" HUMAN MOLECULAR GENETICS, 1999, Vol. 8, No. 5, pp 731-741
		DiFIGLIA, M., et al, "Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain" SCIENCE, Vol. 277, 26 September 1997, pp 1990-1993
		CHERNOFF, Y.O., et al, "Role of the Chaperone Protein Hsp104 in Propagation of the Yeast Prion-Like Factor [psi <sup>+</sup> ]" SCIENCE, Vol. 268, 12 May 1995, pp 880-883
		MARBER, M.S., et al, "Overexpression of the Rat Inducible 70-kD Heat Stress Protein in a Transgenic Mouse Increases the Resistance of the Heart to Ischemic Injury" J. CLIN. INVEST., Vol. 95, April 1995, pp 1446-1456
		SATO, K., et al, "HSP70 is essential to the neuroprotective effect of heat-shock" BRAIN RESEARCH 740 (1996) 117-123
		CHEETHAM, M.E., et al, "Human homologues of the bacterial heat-shock protein DnaJ are preferentially expressed in neurons" BIOCHEM. J., (1992) 284, 469-476
		DeBURMAN, S.K., et al, "Chaperone-supervised conversion of prion protein to its protease-resistant form" PROC. NATL. ACAD. SCI. USA, Vol. 94, pp 13938-13943, December 1997
		ZHOU, M., et al, "Evidence That a Rapidly Turning Over Protein, Normally Degraded by Proteasomes, Regulates hsp72 Gene Transcription in HepG2 Cells" THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 40, October 4, 1996, pp 24769-24775
		WARRICK, J., et al, "Suppression of polyglutamine-mediated neurodegeneration in <i>Drosophila</i> by the molecular chaperone HSP70" Nature Genetics 2, Vol. 23 (1999)
		Bruening, W., et al, "Up-Regulation of Protein Chaperones Preserves Viability of Cells Expressing Toxic Cu/Zn-Superoxide Dismutase Mutants Associated with Amyotrophic Lateral Sclerosis", J. Neurochem. Vol. 72, No. 2, 1999
		Chai, Y., et al., "Analysis of the Role of Heat Shock Protein (HSP) Molecular Chaperones in Polyglutamine Disease", J. Neurosci. 19(23):10338-10347 (1999)

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

RECEIVED

#11317521v1<IPT> -P-1492US1 (#5317521).wpd

SEP 19 2002

TECH CENTER 1600/2900